Tuesday, 20 Mar 2018

You are here

Ohio Sues Five Pharma Companies Over Opioid Epidemic

Ohio is suing five major drug manufacturers, accusing them of misrepresenting the risks of prescription opioid painkillers that has resulted in the current opioid epidemic. The Attorney General of Ohio, Mike DeWine, wants to hold big Pharma responsible for a deadly and costly opioid crisis.

Prescription opioids, including narcotics and heroin, have been linded to a record number (>33,000) deaths in the United States in 2015, according to the Centers for Disease Control and Prevention. One in 5 people (or 2.3 million) in Ohio were prescribed narcotics last year. Which lead to Ohio having one of the nations highest overdose death rates; 4,169 deaths from overdoses last year alone.

In many instances, the victims were killed by heroin cut with fentanyl, smuggled into the country from Mexico or China, thereby rendering the product 25 to 50 times more potent than heroin and 50 to 100 times more potent than morphine according to the U.S. Drug Enforcement Administration.

The suit asserts the drug companies have violated the Ohio Consumer Sales Practices Act, Ohio Corrupt Practices Act, and committing Medicaid fraud and are guilty of disseminating false and misleading statements.

Companies included in the suit were Janssen Pharmaceuticals, Allergan, Purdue Pharma, Endo and Cephalon. Janssen has responded by stating "The allegations in this lawsuit are both legally and factually unfounded."

Other municipalities, such as West Virginia and Mississippi, have also file suits against Pharma for their opioid promotional practices.

Like the cigarette makers, the drug makers relied on "sales representatives" and influential doctors and "seemingly neutral and credible professional societies and patient advocacy groups" to tout the supposed benefits of long-term opioid use "even though there is no 'good evidence' to support" those claims, the suit states.

The author has received compensation as an advisor or consultant on this subject

Rheumatologists' Comments

Dr Cush, I practiced Rheumatology in Ohio from 1980 to 2012. During a period in the late 1980s and 1990s, I recall very clearly that we Ohio physicians were told we were undertreating pain and allowing patients to suffer needlessly. Pain was to be considered the "fifth vital sign" and we were specifically threatened with malpractice if we didn't treat a patient's pain aggressively. Opioids were definitely part of the therapeutic armamentarium". What did a thoughtful doctor do? He/she prescribed opioids, of course. So I have to say it galls me more than a little that drug manufacturers and care providers are now being criticized from all quarters for doing what was essentially demanded of them. I'm not saying we're without blame, but the history and context of this problem needs to be made clear. This is the kind of thing that can happen when non-physicians (i.e. politicians and government folks) try to dictate medical care, even when their motives are quite good. Wm Treuhaft MD Portland, OR

More Like This

Opioid Overdoses Jump 30% in 2017

The CDC released new information yesterday showing that emergency department (ED) visits for opioid overdoses rose 30% in the US from July 2016 through September 2017; in addition, those with an overdose are more likely to a repeat overdose.

The data was presented as part of a new CDC “Vital Signs” report which describes recent trends in healthcare - with this report addressing opioid overdoses using emergency department data.

Opioids No Better than NSAIDs at Chronic Pain

JAMA reports that the SPACE trial demonstrates patients with chronic back or arthritis pain respond equally to 12 months of either opioids or non-opioid (acetaminophen or NSAIDs) analgesics. 

Top 10 MMWR CDC Reports from 2017

Here are the 10 most talked about MMWR Reports of 2017. 

Cannibis Weakly Effective in Neuropathic Pain

The medical use of cannabis is often extended to management of chronic pain and neuropathic pain.

A metanalysis of 27 chronic pain trials show that there is low-strength evidence that cannabis alleviates neuropathic pain but insufficient evidence in other pain populations.

However, there was little evidence that cannabis can alleviate pain associated with multiple sclerosis, cancer, or rheumatic conditions.  

AASM Guidelines for Sleep Apnea Testing

A task force from the American Academy of Sleep Medicine (AASM) performed a systematic review of the scientific literature on obstructive sleep apnea and screening tests.